Clinical Trial Update: Dapagliflozin, Cardio-Metabolic Risk Factors and Type-2 Diabetes [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update assessing the impact of dapagliflozin on cardio-metabolic risk factors in adults with Type 2 Diabetes Mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• FARXIGA (dapagliflozin)

Snippet

Sponsor: University of Palermo | Conditions: Type 2 Diabetes Mellitus | Phase 4 | Status: UNKNOWN